Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionEnsign Peak Advisors, Inc
Latest Disclosed Ownership181,481 shares
Latest Disclosed Value $ 23,908,307
Ensign Peak Advisors, Inc reports 8.47% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 13, 2026 - Ensign Peak Advisors, Inc filed a 13F-HR form disclosing ownership of 181,481 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $23,908,307 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 167,307 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 8.47% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 181,481 14,174 8.47 23,908 0.75 0.0445
2026-02-12 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 167,307 -13,124 -7.27 23,729 -6.31 0.0419
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 180,431 9,648 5.65 25,329 18.00 0.0416
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 170,783 -23,961 -12.30 21,466 -0.34 0.0367
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 194,744 21,050 12.12 21,539 -9.16 0.0412
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 173,694 -1,141 -0.65 23,709 17.70 0.0421
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 174,835 -97,778 -35.87 20,144 -46.33 0.0354
2024-08-13 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 272,613 117,902 76.21 37,531 75.89 0.0686
2024-05-14 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 154,711 82,103 113.08 21,338 123.05 0.0390
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 72,608 -12,613 -14.80 9,567 -0.22 0.0189
2023-11-13 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 85,221 -10,632 -11.09 9,587 6.07 0.0205
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 95,853 27,433 40.10 9,039 30.51 0.0183
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 68,420 16,115 30.81 6,925 10.85 0.0150
2023-02-13 2022-12-31 13F Neurocrine Biosciences COM 64125C109 52,305 7,866 17.70 6,247 32.38 0.0141
2022-11-14 2022-09-30 13F Neurocrine Biosciences COM 64125C109 44,439 -17,036 -27.71 4,719 -21.26 0.0117
2022-08-12 2022-06-30 13F Neurocrine Biosciences COM 64125C109 61,475 -4,515 -6.84 5,993 -3.14 0.0142
2022-05-16 2022-03-31 13F Neurocrine Biosciences COM 64125C109 65,990 -5,862 -8.16 6,187 1.11 0.0126
2022-02-11 2021-12-31 13F Neurocrine Biosciences COM 64125C109 71,852 -35,105 -32.82 6,119 -40.35 0.0117
2021-11-12 2021-09-30 13F Neurocrine Biosciences COM 64125C109 106,957 -2,322 -2.12 10,258 -3.54 0.0214
2021-08-13 2021-06-30 13F Neurocrine Biosciences COM 64125C109 109,279 60,600 124.49 10,635 124.60 0.0215
2021-05-12 2021-03-31 13F Neurocrine Biosciences COM 64125C109 48,679 -125,879 -72.11 4,735 -71.70 0.0102
2021-02-12 2020-12-31 13F Neurocrine Biosciences COM 64125C109 174,558 -33,501 -16.10 16,731 -16.37 0.0379
2020-11-12 2020-09-30 13F Neurocrine Biosciences COM 64125C109 208,059 76,370 57.99 20,007 24.53 0.0506
2020-08-12 2020-06-30 13F Neurocrine Biosciences COM 64125C109 131,689 38,789 41.75 16,066 99.80 0.0437
2020-05-11 2020-03-31 13F Neurocrine Biosciences COM 64125C109 92,900 -17,948 -16.19 8,041 -32.51 0.0269
2020-02-14 2019-12-31 13F Neurocrine Biosciences COM 64125C109 110,848 110,848 11,915 0.0315
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.